We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

How Has The Candesartan Cilexetil Drug Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market for the pharmaceutical drug candesartan cilexetil has seen a robust expansion in the past few years. It is projected to climb from $1.57 billion in 2024 to $1.67 billion in 2025, building at a compound annual growth rate (CAGR) of 6.0%. The growth witnessed in the historical period can be linked to factors like increasing cases of high blood pressure, a growing aging population, a rise in chronic disease incidents, a heightened focus on preventative healthcare, and an upward trend in healthcare spending.

In the coming years, the market for the drug candesartan cilexetil is predicted to experience significant growth, reaching a value of $2.09 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The reason for this anticipated growth during the forecast period includes factors such as increased availability of generic drugs, escalating instances of diseases related to lifestyle, governmental push for cost-effective hypertension care, rising occurrence of cardiovascular diseases, and expanded use of combination therapies. Key trends for the forecast period include a transition towards generic variations of candesartan, the creation of fixed-dose combination drugs, incorporation of digital health for hypertension monitoring, greater emphasis on patient adherence, and intensified research into innovative delivery methods.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24183&type=smp

Which Factors and External Forces Are Driving Demand in the Candesartan Cilexetil Drug Market?

The increasing occurrence of hypertension is projected to drive the growth of the candesartan cilexetil drug market. Hypertension or high blood pressure is a health issue where blood exerts high pressure against artery walls, normally defined as a reading of 130/80 mmHg or more. Factors like poor diet, sedentary lifestyle, and high stress contribute to the rise in hypertension cases. The drug candesartan cilexetil manages hypertension by inhibiting angiotensin II, a hormone that narrows blood vessels, hence calming the arteries and reducing blood pressure. For example, the Centers for Disease Control and Prevention, a US government institution, reported in October 2024 that between August 2021 and August 2023, the prevalence of hypertension saw a significant uptick, increasing by 124.48% within the 18–39 to 40–59 age groups, and a further 36.38% as it moved to those aged 60 and beyond. Consequently, the rising cases of hypertension are triggering a surge in demand in the candesartan cilexetil drug market. Furthermore, the escalation in cardiovascular health problems is expected to drive the growth of the candesartan cilexetil drug market. Cardiovascular disorders, affecting the heart and blood vessels, render the heart less efficient. A sedentary lifestyle can lead to obesity, hypertension, and poor heart health, thus contributing to increased cardiovascular disorders. The medication candesartan cilexetil helps manage these disorders by reducing blood pressure and heart strain, thereby lessening the risk of complications such as heart failure, stroke, and kidney damage. Citing an instance, the British Heart Foundation, a UK-based cardiovascular research charity, reported in January 2025 that approximately 7.6 million people in the UK, including roughly 4 million men and 3.6 million women, were living with heart and circulatory diseases. These conditions account for nearly 27% of all deaths in the country, causing over 170,000 deaths annually or about 480 deaths per day. Therefore, the increasing cases of cardiovascular disorders are fueling the growth of the candesartan cilexetil drug market.

Which Segments in the Candesartan Cilexetil Drug Offer the Most Growth?

The candesartan cilexetil drug market covered in this report is segmented –

1) By Product Type: Tablets, Capsules, Other Product Types

2) By Indication: Hypertension, Heart Failure, Diabetic Nephropathy, Left Ventricular Hypertrophy

3) By Dosage Strength: 4 MG, 8 MG, 16 MG, 32 MG

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Healthcare Facilities

5) By Application: Adult, Children And Adolescent

Subsegments:

1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Dispersible Tablets, Chewable Tablets

2) By Capsules: Hard Gelatin Capsules, Soft Gelatin Capsules, Modified-Release Capsules

3) By Other Product Types: Oral Suspensions, Injectable Formulations, Combination Drug Formulations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24183&type=smp

What Are the Fastest-Growing Geographies in the Candesartan Cilexetil Drug Market?

North America was the largest region in the candesartan cilexetil drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candesartan cilexetil drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive the Candesartan Cilexetil Drug Market’s Growth?

Major players in the candesartan cilexetil drug market are directing their efforts towards creating innovative prescriptions such as hypertension treatments, combined therapies with other antihypertensive medications, and extended-release forms to enhance patient compliance and boost therapeutic outcomes. Hypertension treatment involves the use of medications, lifestyle modifications, and various other measures aimed at managing and decreasing high blood pressure to avoid potential complications such as heart disease, stroke, and kidney damage. For example, in March 2025, US pharmaceutical company Scienture Inc. obtained approval for its SCN-102 New Drug Application, introduced as Arbli, a losartan potassium oral suspension (10 mg/mL) from the US Food & Drug Administration. This formulation of an angiotensin II receptor blocker provides an alternate solution for patients who struggle to swallow tablets, particularly children and the elderly. This development illustrates the increasing interest in alternative dosage formats in the antihypertensive market and highlights the trend towards individualised, user-friendly drug delivery systems.

View the full report here:

https://www.thebusinessresearchcompany.com/report/candesartan-cilexetil-drug-global-market-report

What Are the Key Elements That Define the Candesartan Cilexetil Drug Market?

Candesartan cilexetil drug refers to an angiotensin II receptor antagonist used primarily to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, helping to relax blood vessels and reduce blood pressure.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24183&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model